ClinicalTrials.gg
RecruitingNCT07543731VICTORION-LEAPUpdated Jul 15, 2026

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

An observational study in Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease and Hypercholesterolemia, Familial, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,995
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.

02

Conditions studied

  • Cardiovascular Diseases
  • Atherosclerotic Cardiovascular Disease
  • Hypercholesterolemia, Familial

Keywords

  • Real-world
  • Retrospective
  • Adherence
  • Persistence
  • Long-term
  • PCSK9i
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 5,995 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.

Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients in Italy who initiated inclisiran, evolocumab, or alirocumab treatment during the identification period with at least 18 months of follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
  • Age ≥18 years at index date.
  • With at least 12 months data availability prior to index date.

Exclusion criteria

Exclusion criteria:

  • Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,995 participants (estimated)
Patient registry
No

Groups and cohorts

  • Inclisiran Cohort

    Patients receiving inclisiran injection(s).

  • Evolocumab Cohort

    Patients receiving evolocumab injection(s).

  • Alirocumab Cohort

    Patients receiving alirocumab injection(s).

  • Pooled Anti-PCSK9-mAb Cohort

    Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.

06

What researchers measure

Primary outcomes

  1. Proportion of Days Covered (PDC) With Inclisiran

    PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.

    Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months

  2. Annual PDC With Inclisiran

    PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.

    Time frame: 0-12 months, 12-24 months, 24-48 months

  3. Persistence With Inclisiran Treatment

    Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.

    Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months

Secondary outcomes

  1. PDC With Anti-PCSK9-mAbs

    PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.

    Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months

  2. Annual PDC With Anti-PCSK9-mAbs

    PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.

    Time frame: 0-12 months, 12-24 months, 24-48 months

  3. Persistence With Anti-PCSK9-mAb Treatment

    Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.

    Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months

  4. Baseline Demographics

    Time frame: Baseline

  5. Baseline Clinical Characteristics: Number of Patients by Diagnosis

    Diagnoses include primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD) where available.

    Time frame: Baseline

  6. Baseline Clinical Characteristics: Number of Patients by Comorbidity

    Time frame: Baseline

  7. Baseline Clinical Characteristics: Charlson Comorbidity Index (CCI) Score

    CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).

    Time frame: Baseline

  8. PDC With Lipid Lowering Therapies (LLTs) at Baseline

    PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.

    Time frame: Baseline

  9. Number of Patients by LLTs Received

    Treatment patterns of LLT use. Index date is the date of first use of the treatment.

    Time frame: Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months

  10. Number and Percentage of Patients Receiving Each of the Inclisiran Doses

    Index date is the date of first use of the treatment.

    Time frame: From index date until the end of follow-up, assessed up to 48 months

  11. Time Between Inclisiran Doses

    Index date is the date of first use of the treatment.

    Time frame: From index date until the end of follow-up, assessed up to 48 months

  12. Number of Anti-PCSK9-mAb Prescriptions

    Index date is the date of first use of the treatment.

    Time frame: From index date until the end of follow-up, assessed up to 48 months

  13. Time Between Anti-PCSK9-mAb Prescriptions

    Index date is the date of first use of the treatment.

    Time frame: From index date until the end of follow-up, assessed up to 48 months

  14. Association Between Treatment Adherence and Baseline Characteristics per Cohort

    Multivariable regression models will be used to examine how baseline characteristics could be associated with treatment adherence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.

    Time frame: Baseline, up to 48 months

  15. Association Between Treatment Persistence and Baseline Characteristics per Cohort

    Cox proportional hazards models will be used to examine how baseline characteristics could be associated with treatment persistence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.

    Time frame: Baseline, up to 48 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 22, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07543731
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 2, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion